NASDAQ:PCRXPacira Biosciences Stock Price, Forecast & News

Pacira Biosciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PCRX stock has increased by 28.2% and is now trading at $45.10. View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacira Biosciences.

Pacira Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Pacira Biosciences.

Pacira Biosciences Inc (NASDAQ:PCRX) posted its quarterly earnings data on Thursday, May, 7th. The company reported $0.53 EPS for the quarter, topping the Zacks' consensus estimate of $0.30 by $0.23. The firm earned $105.68 million during the quarter, compared to analysts' expectations of $101.64 million. Pacira Biosciences had a negative net margin of 0.02% and a positive return on equity of 13.89%. Pacira Biosciences's revenue was up 15.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.22 earnings per share. View Pacira Biosciences' earnings history.

14 analysts have issued 12 month price targets for Pacira Biosciences' shares. Their forecasts range from $41.00 to $85.00. On average, they expect Pacira Biosciences' share price to reach $54.50 in the next year. This suggests a possible upside of 20.8% from the stock's current price. View analysts' price targets for Pacira Biosciences.

News headlines about PCRX stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pacira Biosciences earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutPacira Biosciences.

Some companies that are related to Pacira Biosciences include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Celgene (CELG), Clovis Oncology (CLVS), NVIDIA (NVDA), Bausch Health Companies (BHC), Exelixis (EXEL), Micron Technology (MU), Incyte (INCY) and Neurocrine Biosciences (NBIX).

Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX."

Pacira Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.35%), State Street Corp (3.33%), Spyglass Capital Management LLC (2.83%), Clearbridge Investments LLC (2.67%), Frontier Capital Management Co. LLC (2.57%) and Schroder Investment Management Group (1.94%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings, Richard Scranton and Roy Winston. View institutional ownership trends for Pacira Biosciences.

PCRX stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Two Sigma Investments LP, Schroder Investment Management Group, Nuveen Asset Management LLC, Maverick Capital Ltd., Maverick Capital Ltd., Two Sigma Advisers LP, and UBS Group AG. Company insiders that have sold Pacira Biosciences company stock in the last year include Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings, and Richard Scranton. View insider buying and selling activity for Pacira Biosciences.

PCRX stock was bought by a variety of institutional investors in the last quarter, including Spyglass Capital Management LLC, Loomis Sayles & Co. L P, Rice Hall James & Associates LLC, State Street Corp, Russell Investments Group Ltd., Mesirow Financial Investment Management Equity Management, Granahan Investment Management Inc. MA, and Grantham Mayo Van Otterloo & Co. LLC. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace, Mark A Kronenfeld, and Roy Winston. View insider buying and selling activity for Pacira Biosciences.

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PCRX stock can currently be purchased for approximately $45.10.

Pacira Biosciences has a market capitalization of $1.90 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe.

The official website for Pacira Biosciences is www.pacira.com.

Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]